A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for unresectable, locally advanced/metastatic Non-Small Cell Lung Cancer with HER2 mutations

Trial Identifier: D967SC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: October 2021
Primary Completion Date: June 2025
Study Completion Date: March 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations